ICIs activate the patient’s own immune system against the cancer, but off-target effects on the allograft can occur because PD-1 and programmed cell death-ligand 1 (PD-L1) receptors can be found in the allograft and its reactive T cells.31 This evidence concerns the gene PDCD1 and cancer.